John Overdeck’s aTyr Pharma ATYR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $743K | Buy |
1,245,147
+100,582
| +9% | +$65.7K | ﹤0.01% | 3854 |
|
|
2026
Q1 | $893K | Buy |
1,144,565
+690,122
| +152% | +$583K | ﹤0.01% | 3345 |
|
|
2025
Q4 | $356K | Buy |
454,443
+243,443
| +115% | +$200K | ﹤0.01% | 3502 |
|
|
2025
Q3 | $152K | Buy |
211,000
+179,672
| +574% | +$814K | ﹤0.01% | 3418 |
|
|
2025
Q2 | $159K | Buy |
31,328
+9,089
| +41% | +$35.8K | ﹤0.01% | 2951 |
|
|
2025
Q1 | $67.2K | Buy |
22,239
+611
| +3% | +$2.23K | ﹤0.01% | 3009 |
|
|
2024
Q4 | $78.3K | Buy |
+21,628
| New | +$65.5K | ﹤0.01% | 2996 |
|
|
2024
Q2 | – | Sell |
-10,088
| Closed | -$19.7K | – | 3396 |
|
|
2024
Q1 | $19.7K | Sell |
10,088
-16,450
| -62% | -$28.7K | ﹤0.01% | 2932 |
|
|
2023
Q4 | $37.4K | Sell |
26,538
-65,794
| -71% | -$84.4K | ﹤0.01% | 3018 |
|
|
2023
Q3 | $146K | Sell |
92,332
-328,258
| -78% | -$607K | ﹤0.01% | 2699 |
|
|
2023
Q2 | $908K | Buy |
420,590
+294,974
| +235% | +$644K | ﹤0.01% | 1995 |
|
|
2023
Q1 | $264K | Sell |
125,616
-36,922
| -23% | -$80.9K | ﹤0.01% | 2476 |
|
|
2022
Q4 | $356K | Sell |
162,538
-17,476
| -10% | -$41.2K | ﹤0.01% | 2175 |
|
|
2022
Q3 | $540K | Buy |
180,014
+1,457
| +0.8% | +$4.88K | ﹤0.01% | 1744 |
|
|
2022
Q2 | $505K | Sell |
178,557
-56,680
| -24% | -$205K | ﹤0.01% | 1824 |
|
|
2022
Q1 | $1.26M | Sell |
235,237
-251,756
| -52% | -$1.43M | ﹤0.01% | 1594 |
|
|
2021
Q4 | $3.64M | Sell |
486,993
-54,728
| -10% | -$457K | 0.01% | 1411 |
|
|
2021
Q3 | $4.92M | Buy |
541,721
+527,275
| +3,650% | +$3.15M | 0.01% | 1240 |
|
|
2021
Q2 | $70K | Buy |
+14,446
| New | +$61.5K | ﹤0.01% | 3936 |
|
|
2021
Q1 | – | Sell |
-46,826
| Closed | -$182K | – | 4323 |
|
|
2020
Q4 | $182K | Sell |
46,826
-105,648
| -69% | -$386K | ﹤0.01% | 3128 |
|
|
2020
Q3 | $492K | Buy |
152,474
+20,351
| +15% | +$83.6K | ﹤0.01% | 2262 |
|
|
2020
Q2 | $587K | Buy |
132,123
+67,854
| +106% | +$246K | ﹤0.01% | 1887 |
|
|
2020
Q1 | $180K | Buy |
+64,269
| New | +$277K | ﹤0.01% | 2694 |
|
|
2019
Q3 | – | Sell |
-2,792
| Closed | -$14K | – | 3861 |
|
|
2019
Q2 | $14K | Sell |
2,792
-2,015
| -42% | -$13.7K | ﹤0.01% | 3266 |
|
|
2019
Q1 | $37K | Sell |
4,807
-2,921
| -38% | -$20.8K | ﹤0.01% | 2948 |
|
|
2018
Q4 | $54K | Buy |
7,728
+315
| +4% | +$2.64K | ﹤0.01% | 2861 |
|
|
2018
Q3 | $84K | Buy |
7,413
+6,499
| +711% | +$71.1K | ﹤0.01% | 3086 |
|
|
2018
Q2 | $12K | Buy |
+914
| New | +$21.7K | ﹤0.01% | 3244 |
|
Other funds holding ATYR
GCP
KCM
John Overdeck's ATYR Position: Q2 2026 in Review
John Overdeck increased its aTyr Pharma (ATYR) stake by 8.8% in Q2 2026, buying an estimated $65.7K and bringing the position to 1,245,147 shares worth $743K. The position accounts for ﹤0.01% of the portfolio, ranked #3854.
John Overdeck first reported a position in ATYR in Q2 2018 and has held it in 28 quarters since. The position peaked at $4.92M in Q3 2021. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.
- John Overdeck held 1,245,147 shares of aTyr Pharma worth $743K as of Q2 2026.
- John Overdeck bought 100,582 aTyr Pharma shares in Q2 2026, an estimated $65.7K.
- aTyr Pharma made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3854 holding.
- John Overdeck first reported a position in aTyr Pharma in Q2 2018 and has held it in 28 quarters since.
- John Overdeck's aTyr Pharma position peaked at $4.92M in Q3 2021.
- 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.